RESI Boston June 2023

Life Science Nation is hosting a RESI conference which will be hybrid, June 5-7th. It will take place onsite on Monday June 5th at the Westin Copley Place from 8am – 5pm Eastern Time, and digitally on the 6th and 7th on the Partnering Platform. LSN is offering Arizona Bioindustry Association (AZBio) members a discounted registration for their early-stage startupsContinue reading

Aqualung Therapeutics Concludes ALT-100 Antibody (mAb) Dosing in Its P1a Study with no Reported SAE’s. Will Engage FDA for Clearance of the P2a PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients

TUCSON, AZ / ACESSWIRE / January 31, 2023 / Aqualung Therapeutics, an early stage immunotherapeutics company with a novel anti-inflammatory and anti-fibrotic therapeutic platform for life-threatening unchecked inflammation/fibrosis, today announced that it has engaged Novotech, a leading Asia Pacific centered, full-service contract research organization (“CRO”) in the Asia-Pacific, United States and Europe, for its upcoming Phase 2a PUERTA clinical trial utilizing the humanized ALT-100 mAb. Aqualung currently plans to initiate its Phase 2a clinical trial in Australia starting in Q2 2023. The study will enroll moderate/severe ARDS subjects in hospital locations in Australia as well at multiple sites in the United States.Continue reading

HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series

TUCSON, Ariz., Dec. 09, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced it will host its next HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis”, on Tuesday, December 13, 2022 at 11:00 am Eastern Standard Time.Continue reading

Researchers develop drug to treat Alzheimer’s disease in Down syndrome patients

When a baby is born, each cell in his or her body contains 23 pairs of chromosomes or 46 chromosomes in total, with half coming from each parent. At least, this is the case most of the time.

Yet, the biological machinery responsible for assuring proper chromosome distribution sometimes goes awry. This can result in a range of serious genetic diseases, the most common of which is Down syndrome. In this case, an extra copy of chromosome 21 is inherited from one parent. The condition is also known as Trisomy 21.Continue reading

Vidium Animal HealthⓇ and Torigen Pharmaceuticals Partner to Increase Accessibility of Advanced Cancer Care for Canine Patients


PHOENIX—October 11, 2022Vidium Animal Health announced today that it has partnered with Torigen Pharmaceuticals, an animal health biologics company, to offer genomic testing and precision medicine to more veterinarians. By opening up the use of personalized, precision medicine to the veterinary marketplace, Vidium and Torigen are providing specialists and general practicing veterinarians with more options to advance the care of dogs with cancer.Continue reading

ASU professor to study new genome editing tools with NIH Innovator Award

There are many human genetic diseases — for example, sickle-cell disease, cystic fibrosis and Hutchinson-Gilford progeria syndrome — that currently have no cure and are caused by point mutations, for which there is a pressing need to develop precision genome editing tools able to correct these mutations with high efficiency and accuracy.

Assistant Professor Audrey Lapinaite from Arizona State University’s School of Molecular Sciences and the Biodesign Institute’s ASU-Banner Neurodegenerative Disease Research Center is working on this problem and has just been awarded a prestigious National Institutes of Health (NIH) Director’s New Innovator Award.Continue reading